Several drug associations in the clinical analysis of the TCGA cohort showed cancer-specific patterns of sensitivity/resistance, which may be attributable to the heterogeneity of patient data, as well as differences in clinical and phenotypic features associated with BUB1. The gene discussed is BUB1; the disease is cancer.